Are you Dr. Mobasher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 39 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
875 Blake Wilbur Drive
Stanford Cancer Center
Stanford, CA 94305Phone+1 650-723-7621Fax+1 650-723-6661- Is this information wrong?
Summary
- Dr. Mehrdad Mobasher, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2007 - 2010
University of California (Irvine)Residency, Internal Medicine, 2004 - 2007
Tehran University of Medical Sciences School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2024
Clinical Trials
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Start of enrollment: 2019 May 03
Publications & Presentations
PubMed
- 47 citationsPrognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, po...Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yeung-Chul Mun, Neil E. Kay, Tait D. Shanafelt, Kari G. Rabe, John C. Byrd, Asher Chanan-Khan, Richard...> ;The Lancet. Haematology. 2019 Jul 1
- 52 citationsPhase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.Ian W. Flinn, John G. Gribben, Martin J. S. Dyer, William G. Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, Kerry A. Rogers, Swaminathan P. Iyer, Anne Qui...> ;Blood. 2019 Jun 27
- 92 citationsVenetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Carla Casulo, Steven Le Gouill, Laurie H. Sehn, Hervé Tilly, Guillaume Cartron, Martine E.D. Chamuleau, Andre Goy, C...> ;Blood. 2019 May 2
- Join now to see all
Press Mentions
(Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRAJanuary 19th, 2023- BRUKINSA® Approved in the U.S. For Chronic Lymphocytic LeukemiaJanuary 19th, 2023
- BRUKINSA® (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRAJanuary 19th, 2023
- Join now to see all
